[
    [
        {
            "time": "2018-03-15",
            "original_text": "Were Hedge Funds Right About AbbVie (ABBV)?",
            "features": {
                "keywords": [
                    "Hedge Funds",
                    "Right",
                    "AbbVie"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Were Hedge Funds Right About AbbVie (ABBV)?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "AbbVie Receives Health Canada Approval of HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Moderately to Severely Active Ulcerative Colitis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Health Canada",
                    "Approval",
                    "HUMIRA",
                    "Pediatric",
                    "Ulcerative Colitis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Receives Health Canada Approval of HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Moderately to Severely Active Ulcerative Colitis",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Is It Time To Buy AbbVie Stock As It Barrels Toward A New Buy Point?",
            "features": {
                "keywords": [
                    "Buy",
                    "AbbVie",
                    "Stock",
                    "Buy Point"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is It Time To Buy AbbVie Stock As It Barrels Toward A New Buy Point?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 6
            }
        }
    ]
]